Condition
Tumor-Induced Osteomalacia
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Unknown2
Recruiting1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07366099Not ApplicableRecruitingPrimary
Al18F-NOTA-LM3 PET/CT in Patients With TIO
NCT03775187Unknown
Expanded Access to Burosumab
NCT03510455Phase 2TerminatedPrimary
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
NCT04689893Phase 1UnknownPrimary
Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO
Showing all 4 trials